John Brottem Sells 2,632 Shares of Outset Medical (NASDAQ:OM) Stock

Outset Medical, Inc. (NASDAQ:OM) General Counsel John Brottem sold 2,632 shares of Outset Medical stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $4.39, for a total transaction of $11,554.48. Following the completion of the sale, the general counsel owned 87,475 shares in the company, valued at approximately $384,015.25. This trade represents a 2.92% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Outset Medical Stock Up 2.9%

OM stock opened at $4.30 on Thursday. The stock has a market capitalization of $80.84 million, a P/E ratio of -1.05 and a beta of 1.96. The firm has a 50-day simple moving average of $4.57 and a 200-day simple moving average of $4.23. The company has a quick ratio of 4.11, a current ratio of 5.19 and a debt-to-equity ratio of 1.03. Outset Medical, Inc. has a 52 week low of $3.00 and a 52 week high of $16.16.

Outset Medical (NASDAQ:OM) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.08). Outset Medical had a negative net margin of 63.06% and a negative return on equity of 61.67%. The company had revenue of $31.64 million during the quarter, compared to analysts’ expectations of $28.97 million. Equities analysts forecast that Outset Medical, Inc. will post -3.8 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Legal & General Group Plc acquired a new position in shares of Outset Medical during the 2nd quarter worth approximately $34,000. BNP Paribas Financial Markets lifted its position in Outset Medical by 7,013.8% during the second quarter. BNP Paribas Financial Markets now owns 2,063 shares of the company’s stock worth $40,000 after buying an additional 2,034 shares in the last quarter. New York State Common Retirement Fund acquired a new position in Outset Medical during the second quarter worth $108,000. Los Angeles Capital Management LLC purchased a new stake in Outset Medical in the 4th quarter valued at $29,000. Finally, Quantbot Technologies LP acquired a new stake in shares of Outset Medical in the 2nd quarter worth $152,000.

Analyst Ratings Changes

A number of analysts have recently issued reports on the company. Wall Street Zen raised Outset Medical from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. TD Cowen restated a “buy” rating on shares of Outset Medical in a report on Friday, May 8th. Finally, Weiss Ratings raised shares of Outset Medical from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, August 7th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Outset Medical presently has an average rating of “Hold” and an average price target of $10.00.

About Outset Medical

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.